Revolution Medicines' Pancreatic Cancer Drug RMC-9805 Shows 30% Response Rate in Early Trials
Portfolio Pulse from Benzinga Newsdesk
Revolution Medicines' RMC-9805 shows a 30% response rate in early trials for pancreatic cancer, indicating potential as a treatment for RAS-addicted cancers. The drug demonstrated a favorable safety profile and significant antitumor activity, with a disease control rate of 80%.
October 25, 2024 | 8:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revolution Medicines' RMC-9805 shows a 30% response rate in early trials for pancreatic cancer, indicating potential as a treatment for RAS-addicted cancers. The drug demonstrated a favorable safety profile and significant antitumor activity, with a disease control rate of 80%.
The positive early trial results for RMC-9805, including a 30% response rate and 80% disease control rate, suggest potential for the drug in treating pancreatic cancer. This could lead to increased investor confidence and a positive impact on RVMD's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100